Jazz Pharmaceuticals (JAZZ) EBT (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly EBT of $299.2 million for Q1 2026, up 372.5% year-over-year from $63.3 million in Q1 2025, and up 43.52% quarter-over-quarter from $208.5 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) EBT (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $299.2 million for Q1 2026.
- In Q1 2026, EBT rose 372.5% year-over-year to $299.2 million; the TTM figure through Mar 2026 stood at -$218.8 million (down 160.43% YoY), while the FY2025 annual figure was -$627.9 million, down 233.49% from the prior year.
- EBT for Q1 2026 stood at $299.2 million, up from $208.5 million in the prior quarter.
- The five-year high for EBT was $299.2 million in Q1 2026, with the low at -$735.6 million in Q2 2025.
- The 5-year median for EBT is $55.1 million (2023), against an average of $3.9 million.
- The sharpest annual moves came in 2023 and 2025: EBT soared 771.16% in 2023, then tumbled 6753.93% in 2025.
- Jazz Pharmaceuticals' EBT stood at -$340.0 million in 2022, then soared by 118.1% to $61.5 million in 2023, then jumped by 116.52% to $133.2 million in 2024, then surged by 56.49% to $208.5 million in 2025, then soared by 43.52% to $299.2 million in 2026.
- Business Quant data shows JAZZ's EBT at $299.2 million in Q1 2026, $208.5 million in Q4 2025, and $9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 211.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211.00 Mn |
| Mar 31, 2026 | 299.20 Mn |
| Dec 31, 2025 | 208.47 Mn |
| Sep 30, 2025 | 9.04 Mn |
| Jun 30, 2025 | -735.55 Mn |
| Mar 31, 2025 | -109.80 Mn |
| Dec 31, 2024 | 133.22 Mn |
| Sep 30, 2024 | 200.81 Mn |
| Jun 30, 2024 | 137.93 Mn |
| Mar 31, 2024 | -1.60 Mn |
| Dec 31, 2023 | 61.53 Mn |
| Sep 30, 2023 | 99.52 Mn |
| Jun 30, 2023 | 81.78 Mn |
| Mar 31, 2023 | 55.10 Mn |
| Dec 31, 2022 | -339.99 Mn |
| Sep 30, 2022 | -60.13 Mn |
| Jun 30, 2022 | 21.01 Mn |
| Mar 31, 2022 | 6.33 Mn |
| Dec 31, 2021 | -44.83 Mn |
| Sep 30, 2021 | -67.63 Mn |